Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Hematology
Volume 2015 (2015), Article ID 318545, 5 pages
http://dx.doi.org/10.1155/2015/318545
Case Report

Translocation (6;15)(q12;q15): A Novel Mutation in a Patient with Therapy-Related Myelodysplastic Syndrome

1Department of Pathology and Laboratory Medicine, University of California Davis Medical Center, Sacramento, CA 95817, USA
2Department of Internal Medicine, Division of Hematology and Oncology, University of California Davis Medical Center, Sacramento, CA 95817, USA

Received 5 November 2015; Accepted 6 December 2015

Academic Editor: Kiyotaka Kawauchi

Copyright © 2015 Saba F. Ali et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. H. Swerdlow, E. Campo, N. L. Harris et al., World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, International Agency for Research on Cancer (IARC), Lyon, France, 4th edition, 2008.
  2. C. Seedhouse and N. Russell, “Advances in the understanding of susceptibility to treatment-related acute myeloid leukaemia,” British Journal of Haematology, vol. 137, no. 6, pp. 513–529, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Y. Ok, R. P. Hasserjian, P. S. Fox et al., “Application of the international prognostic scoring system-revised in therapy-related myelodysplastic syndromes and oligoblastic acute myeloid leukemia,” Leukemia, vol. 28, no. 1, pp. 185–189, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. T. Wong, G. Ramsingh, A. L. Young et al., “Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia,” Nature, vol. 518, no. 7540, pp. 552–555, 2015. View at Publisher · View at Google Scholar
  5. E. Schulz, K. Kashofer, E. Heitzer et al., “Preexisting TP53 mutation in therapy-related acute myeloid leukemia,” Annals of Hematology, vol. 94, no. 3, pp. 527–529, 2015. View at Publisher · View at Google Scholar
  6. S. M. Smith, M. M. Le Beau, D. Huo et al., “Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series,” Blood, vol. 102, no. 1, pp. 43–52, 2003. View at Publisher · View at Google Scholar
  7. L. A. Godley and R. A. Larson, “Therapy-related myeloid leukemia,” Seminars in Oncology, vol. 35, no. 4, pp. 418–429, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. W. Kern, T. Haferlach, S. Schnittger, W. Hiddemann, and C. Schoch, “Prognosis in therapy-related acute myeloid leukemia and impact of karyotype,” Journal of Clinical Oncology, vol. 22, no. 12, pp. 2510–2511, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. D. Coso, R. Costello, R. Cohen-Valensi et al., “Acute myeloid leukemia and myelodysplasia in patients with chronic lymphocytic leukemia receiving fludarabine as initial therapy,” Annals of Oncology, vol. 10, no. 3, pp. 362–363, 1999. View at Publisher · View at Google Scholar · View at Scopus
  10. J. O. Armitage, P. P. Carbone, J. M. Connors, A. Levine, J. M. Bennett, and S. Kroll, “Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients,” Journal of Clinical Oncology, vol. 21, no. 5, pp. 897–906, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. B. A. Jonas and P. L. Greenberg, “MDS prognostic scoring systems—past, present, and future,” Best Practice & Research Clinical Haematology, vol. 28, no. 1, pp. 3–13, 2015. View at Publisher · View at Google Scholar
  12. Z. N. Singh, D. Huo, J. Anastasi et al., “Therapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevant,” American Journal of Clinical Pathology, vol. 127, no. 2, pp. 197–205, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. P. L. Greenberg, H. Tuechler, J. Schanz et al., “Revised international prognostic scoring system for myelodysplastic syndromes,” Blood, vol. 120, no. 12, pp. 2454–2465, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. P. M. L. Ming, D. M. Goodner, and T. S. Park, “Chromosome 6/15 translocation with multiple congenital anomalies,” Obstetrics and Gynecology, vol. 49, no. 2, pp. 251–253, 1977. View at Google Scholar · View at Scopus
  15. C. V. Fernandez, V. S. Lestou, J. Wildish, C. L. Y. Lee, and P. H. B. Sorensen, “Detection of a novel t(6;15)(q21;q21) in a pediatric Wilms tumor,” Cancer Genetics and Cytogenetics, vol. 129, no. 2, pp. 165–167, 2001. View at Publisher · View at Google Scholar · View at Scopus
  16. M. J. Macera, M. A. Sanchez, A. M. Elizalde, S. K. Gogineni, and R. S. Verma, “New translocations [t(6;15)(p25;q22) and t(6;19)(q16;q13.3)] with t(9;22)(q34;q11) in a Ph-positive chronic myelogenous leukemia,” Cancer Genetics and Cytogenetics, vol. 72, no. 1, pp. 65–67, 1994. View at Publisher · View at Google Scholar · View at Scopus
  17. V. Eclache, F. Viguie, C. Frocrain et al., “A new variant t(6;15;17)(q25;q22;q21) in acute promyelocytic leukemia: fluorescence in situ hybridization confirmation,” Cancer Genetics and Cytogenetics, vol. 159, no. 1, pp. 69–73, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. C. T. Cummings, D. DeRyckere, H. S. Earp, and D. K. Graham, “Molecular pathways: MERTK signaling in cancer,” Clinical Cancer Research, vol. 19, no. 19, pp. 5275–5280, 2013. View at Publisher · View at Google Scholar
  19. A. Schinzel, “Microdeletion syndromes, balanced translocations, and gene mapping,” Journal of Medical Genetics, vol. 25, no. 7, pp. 454–462, 1988. View at Publisher · View at Google Scholar · View at Scopus